Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome. NLM AIDSLINE Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome.

Eur J Cancer. 1999 Dec;35(13):1809-15. Unique Identifier : AIDSLINE MED/20138951
Cattelan AM; Calabro ML; Aversa SM; Zanchetta M; Meneghetti F; De Rossi A; Chieco-Bianchi L; Department of Infectious Diseases, General Hospital of Padova,; Italy.


Abstract: The clinical response of AIDS-related Kaposi's sarcoma (KS) to highly active antiretroviral therapy (HAART), a combination of human immunodeficiency virus type 1 (HIV-1) protease and reverse transcriptase inhibitors, was studied in 11 patients, all but one with progressive KS. CD4+ cell counts, plasma HIV-1 RNA levels, and antibody titres to lytic ORF65 and latency-associated human herpes virus type 8 (HHV-8) proteins were determined in sequential samples. Six complete and three partial clinical responses were achieved in a median time of 6 and 3 months, respectively, and confirmed after a median time of 16 months on HAART. 2 patients showed disease progression. A consistent decrease in HIV-1 RNA levels, paralleled by an increase in CD4+ cell counts, was observed in all patients who showed complete or partial clinical response; HIV-1 RNA levels remained persistently high in the two patients who progressed, despite a change in HAART. HHV-8 antibody titres were generally higher in patients with mucosal/visceral involvement compared with patients with limited disease; a decrease in ORF65 antibody titre was significantly associated with a clinical response. These results indicate that HAART is effective for AIDS-related KS; the clinical response correlates with a decrease in plasma HIV-1 RNA levels, an increase in CD4+ lymphocytes, and a decrease in antibodies to ORF65 HHV-8 protein.


Keywords: JOURNAL ARTICLE Adult Antibodies, Viral/ANALYSIS CD4 Lymphocyte Count Drug Combinations Herpesvirus, Kaposi Sarcoma-Associated/IMMUNOLOGY/ISOLATION & PURIF Human HIV Protease Inhibitors/*THERAPEUTIC USE HIV-1/IMMUNOLOGY/ISOLATION & PURIF Male Middle Age Reverse Transcriptase Inhibitors/*THERAPEUTIC USE Sarcoma, Kaposi/*DRUG THERAPY/VIROLOGY Support, Non-U.S. Gov't Treatment Outcome Viral LoadKWDjournalarticleadultantibodies,viral/analysiscd4lymphocytecountdrugcombinationsherpesvirus,kaposisarcoma-associated/immunology/isolation&purifhumanhivproteaseinhibitors/KWDtherapeuticusehiv-1/immunology/isolation&purifmalemiddleagereversetranscriptaseinhibitors/KWDtherapeuticusesarcoma,kaposi/KWDdrugtherapy/virologysupport,non-uKWDsKWDgov'ttreatmentoutcomeviralload
000530
A0052241

Copyright © 2000 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .